Related by context. All words. (Click for frequent words.) 72 Small Molecule 69 Alvine Pharmaceuticals 68 Therapeutic Antibody 68 RNAi Therapeutics 68 Immunotherapeutic 68 Initiates Clinical 67 M.D. Ph.D. 67 ImmunoCellular Therapeutics 67 Presents Preclinical Data 67 Chiron Diagnostics 67 Metabolic Disease 67 EnVivo 67 RNA Therapeutics 66 Antisense 66 Antisense Drug 66 Cancer Immunotherapy 66 Oncology Merck Serono 66 Phase 2b Clinical Trial 66 Inflammatory Diseases 66 Regulus Therapeutics 66 Immunex Corporation 66 molecular imaging radiopharmaceutical 66 BiTE Antibody 66 Drug Metabolism 66 Dr Andreas Hohlbaum 66 Initiates Clinical Trial 65 Cancer Vaccines 65 Novel Therapies 65 HCV Protease Inhibitor 65 Antibody Discovery 65 Tezampanel 65 Completes Patient Enrollment 65 pralatrexate injection folate analogue 65 Initiates Phase III 65 Anti Infective 65 Therapeutic Vaccines 65 Idera Pharmaceuticals 65 Hoyoung Huh 65 Receives Milestone Payment 65 Creabilis Therapeutics 65 RNAi Therapeutic 65 Bayhill Therapeutics 65 Arno Therapeutics 65 Clinical Trial Results 65 Catalyst Biosciences 65 Kinase Inhibitor 65 Presents Positive 64 Founding Scientist 64 IL# PE#QQR 64 Ridaforolimus 64 JAK2 Inhibitor 64 Zelos Therapeutics 64 ARRY # 64 Receives Orphan Drug 64 KAI Pharmaceuticals 64 Mimetics 64 Bioanalysis 64 PsychoGenics 64 Inflammatory Arthritis 64 Medicinal Chemistry 64 EnVivo Pharmaceuticals 64 Phase 2b Trial 64 Emisphere Technologies 64 Cellular Immunology 64 Molecular Virology 64 Initiates Enrollment 64 Collaborators Publish 64 Genaera Corporation 64 Amira Pharmaceuticals 64 Drug Discovery 64 Phase IIb Clinical Trial 64 Infinity Pharmaceuticals 64 Liprotamase 64 Aerovance 64 Begins Dosing 64 Resolvyx Pharmaceuticals 64 Quark Pharmaceuticals 64 Michele Garufi Chairman 64 Drug Repositioning 64 Dr. Arndt Schottelius 64 Agios Pharmaceuticals 64 Immunotherapeutics 64 Receptos 64 Hematide ™ 64 Aegera 63 Present Preclinical Data 63 Metabasis Therapeutics Inc. 63 Alnylam Nasdaq ALNY 63 Genetic Therapy 63 telomerase therapeutic 63 Personalized Immunotherapy 63 Regado Biosciences 63 Romidepsin 63 Anti Infectives 63 Receives Orphan Drug Designation 63 Novel Therapeutic 63 Successfully Completes Phase 63 Epiphany Biosciences 63 Hematological Malignancies 63 InfaCare 63 Lexicon Pharmaceuticals 63 Small Molecule Drug 63 Peptimmune 63 Eric von Hofe 63 Christoph Westphal MD Ph.D. 63 Chemokine Therapeutics 63 stated Belinda Tsao 63 Conatus Pharmaceuticals 63 Paul Laikind 63 Ron Bentsur Chief Executive 63 Patient Enrollment 63 Senetek PLC 63 Personalised Medicine 63 t2cure GmbH 63 Drug Candidate 63 Anders Gersel Pedersen 63 Meets Primary Endpoint 63 Quark Biotech 63 HDL Mimetic Peptide 63 Files IND 63 Therapeutic Potential 62 Galenea 62 Wellstat 62 Therapeutic Competitors Companies 62 Marillion Pharmaceuticals 62 Protein Therapeutics 62 Biomarker Study 62 Kirsten Drejer 62 Oncology Drug 62 Synta Pharmaceuticals 62 FOLOTYN ® 62 Georges Gemayel 62 Elixir Pharmaceuticals 62 ERYtech 62 Dr. Boro Dropulic 62 Cardiovascular Therapeutics 62 Preclinical Data 62 Therapeutic Vaccine 62 MultiCell Technologies 62 Homspera TM 62 Anti Angiogenic 62 Ph.D. Targacept 62 Patrice Milos 62 Quark Biotech Inc. 62 AFFiRiS 62 Elliott Sigal 62 Procyon Biopharma 62 Per Olof Wallström 62 Initiates Phase II 62 David Schenkein MD 62 Phenomix Corporation 62 Exploratory Clinical 62 CEQ# 62 HDAC Inhibitor 62 Cancer Immunotherapeutics 62 Anti Tumor 62 MD FACS FAAP 62 Genitope Corporation 62 NovaBay Pharmaceuticals 62 novel therapeutic antibodies 62 ProtoKinetix 62 Surface Logix 62 Anticancer Agent 62 Hematologic Malignancies 62 GSK '# 62 SIX RO ROG 62 Trellis Bioscience 62 James Sapirstein 62 NicOx commented 62 Investigational Compound 62 Avila Therapeutics 62 Locus Pharmaceuticals 62 Monoclonal Antibody 62 Athena Neurosciences 62 Aptamer 62 Taligen Therapeutics 62 X Ceptor Therapeutics 62 Protalex Inc. 62 Taligen 62 siRNA Delivery 62 Clinical Outcome 62 Therapeutic Competitors companiesandmarkets.com adEgemonye 62 MEK Inhibitor 62 AVEO Pharmaceuticals 62 Ascenta Therapeutics 62 NormOxys 62 Ostabolin C TM 62 Biologics Manufacturing 62 Inflammatory Disease 62 AMEX KAL 62 Ulrich Dauer CEO 62 Anticancer Drug 62 rxRNA 62 Mr. Ellberger 62 Psoriasis Drug 61 TRO# 61 Vaccine Adjuvant 61 Nasdaq HALO 61 CEO Tod Woolf 61 GVAX ® 61 Cerus Corporation 61 Nuon Therapeutics 61 Safinamide 61 Cylene Pharmaceuticals 61 GSK Oncology 61 cMET 61 Hsp# Inhibitor 61 Licenses Novel 61 RNA Interference 61 Robert L. Bratzler 61 Affimed Therapeutics AG 61 IND Filing 61 Agouron Pharmaceuticals 61 Hybridon 61 Kinase Inhibitors 61 Phase 2a Clinical Trial 61 Awarded Qualifying Therapeutic 61 Synthetic Peptide 61 VIRxSYS 61 Protein Expression 61 Lipid Sciences 61 OTCBB IMUC 61 Ichor Medical Systems 61 Tibotec BVBA 61 Dr. Declan Doogan 61 Zosano 61 Menelas Pangalos 61 Euroscreen 61 Altus Pharmaceuticals 61 ESBATech AG 61 Solid Tumor 61 Cerimon Pharmaceuticals 61 Tumor Microenvironment 61 candidate deforolimus 61 LEAD Therapeutics 61 Cetrorelix 61 Autoimmune Disease 61 Biomarker Discovery 61 Experimental Hematology 61 Arisaph Pharmaceuticals 61 TransMolecular 61 Reports Preclinical Data 61 TRACON Pharmaceuticals 61 SinuNase ™ 61 Archemix Corp. 61 Nicholas Nicolaides 61 Therapeutic Competitors Report 61 Metabolex 61 ASGCT 61 Sunesis Pharmaceuticals 61 Ambrx 61 Computational Chemistry 61 non nucleoside inhibitor 61 Xcytrin R 61 ImQuest 61 Safi Bahcall Ph.D. 61 Enobia 61 Islet Transplantation 61 Phase 1b Clinical Trial 61 CardioVascular BioTherapeutics 61 Amarantus 61 enGene 61 Panzem R 61 Palatin Technologies 61 Develop Novel 61 Anthony Giovinazzo 61 +#-#-#-# @ russopartnersllc.com 61 Syntonix 61 THR beta agonist 61 Nuclear Receptors 61 Thomas Ichim 61 Bionanotechnology 61 Neuronyx Inc. 61 Earns Milestone Payment 61 Inc Therapeutic Competitors 61 Gout Drug 61 platform HDL Mimetic 61 Dr. Wolfgang Wein 61 Signal Transduction 61 Yuval Cohen 61 Radiopharmaceutical 61 BioRexis 61 Phase III Trial 61 Kazumi Shiosaki 61 SUTENT ® 61 Novel Antibiotic 61 Pafuramidine 61 Squalamine 61 Ercole Biotech 61 CorporateCommunications +#-#-#-# 61 Neil K. Warma 61 Phase III Clinical Trial 61 Eric Rowinsky MD 61 Daniel Junius 61 Cenomed 61 Anat Cohen Dayag 61 Systemic Delivery 61 Xenon Pharmaceuticals 61 Anticancer Compound 61 Dr. Masamichi Koike 61 Immutep 61 Trophos 61 ProLindac TM 61 Relypsa 61 Receive Milestone Payment 61 Receives Approvable Letter 61 GendeLLindheim BioCom Partners 61 Archemix 61 Enanta Pharmaceuticals 61 Therapeutic Protein 61 ViroStatics 60 Corixa Corporation 60 Adenosine Therapeutics 60 AAG geldanamycin analog 60 Dale Pfost 60 Nereus Pharmaceuticals 60 Recombinant Human 60 ALN PCS 60 Ardea Biosciences 60 Cerimon Pharmaceuticals Inc. 60 Gemin X 60 HuCAL GOLD R 60 Submits Response 60 GATTEX TM 60 Metabolic Diseases 60 FoldRx Pharmaceuticals Inc. 60 Tod Woolf Ph.D. 60 Neurotherapeutics 60 Archexin 60 Hana Biosciences 60 Clinical Proteomics 60 oncolytic virus therapies 60 ALTROPANE R 60 aTyr Pharma 60 Vaccinex 60 Antibody Therapeutics 60 Lung Cancer Drug 60 Vicor Technologies 60 Synthetic Chemistry 60 Ceregene 60 Dan Zabrowski 60 Anaphore 60 Exploit collaboration 60 Novel Treatments 60 JAK1 60 Raymond T. Bartus 60 Monoclonal Antibodies 60 Carfilzomib 60 Christos Mantzoros 60 TKB# 60 MBRX 60 XTLbio 60 CD# CEA 60 Axxam 60 PhaseBio 60 Submits NDA 60 Molecular Evolution 60 Craig Tooman 60 DMD DMSc 60 Juergen Engel Ph.D. 60 Daniel Von Hoff 60 ESBATech 60 Ion Channels 60 pan HDAC inhibitor 60 Agile Therapeutics 60 Biopharmaceutical Industry 60 investigational humanized monoclonal antibody 60 ALN TTR 60 Mihael Polymeropoulos MD 60 MKC# MKC# PP 60 non nucleoside HCV 60 Inc. Nasdaq IMGN 60 Commences Phase 60 TargeGen 60 Inovio Pharmaceuticals 60 Pivotal Phase II 60 AMEX REX 60 Cara Therapeutics 60 Investigational Treatment 60 OTCBB PYTO 60 AMEX RGN 60 Hydra Biosciences 60 Antigen Specific 60 Factor Receptor 60 Hepatocellular Carcinoma 60 ThromboGenics commenting 60 Barry D. Quart 60 Sylvie Gregoire 60 Neurodegenerative Diseases 60 Regeneron Pharma 60 Vincent Mutel CEO 60 Immunobiology 60 Epizyme 60 novel peptides 60 VentiRx 60 Gastrointestinal Cancers 60 Coley Pharmaceutical Group 60 Nasdaq IDRA 60 Merrimack Pharmaceuticals 60 Translational Biology 60 Xytis 60 Nasdaq IDRA today 60 Michael V. Novinski 60 Renal Cancer 60 Afferent Pharmaceuticals 60 Marc Tessier Lavigne 60 Chemokine 60 Omacetaxine 60 Locked Nucleic Acid 60 Announces Poster Presentations 60 Immunotherapies 60 Ron Bentsur 60 Smooth Muscle 60 Dr. Michelle Berrey 60 InNexus Biotechnology 60 AGY Therapeutics 60 Confirms Efficacy 60 Metaphore 60 Preclinical Evaluation 60 Fabry Disease 60 First Patient Dosed 60 Companion Diagnostic 60 Prolexys 60 Semafore 60 Howard Fillit MD 60 Develops Novel 60 See CLINICAL PHARMACOLOGY 60 Completes Dosing 60 MedChem 60 Cerimon 60 Biostatistical 60 Albugon 60 Aegis Therapeutics 60 DermTech International 60 Welichem 60 Tissue Repair 60 Alder Biopharmaceuticals 60 targeted radiotherapeutic 60 selective immunoproteasome inhibitor 60 Novel Antibody 60 elbion 60 Molecular Insight 60 Vical Incorporated 60 Celator 60 Migraine Drug 60 Nanobac Pharmaceuticals 60 ALN HPN 60 CureDM 60 Nuvelo Announces 60 oral proteasome inhibitor 60 OSI Oncology 60 Loïc Maurel MD 60 subsidiaries visit http:/www.apricusbio.com 60 Phase IIb Trial 60 AVAX 60 Maven Semantic 60 Therapeutic Targets 60 Portola Pharmaceuticals 60 VasoGenix Pharmaceuticals 60 Milestone Payment 59 Preclinical Studies 59 Rosty Raykov Chief Executive 59 targeting CD# 59 Collaborators Present 59 Logical Therapeutics 59 Prostate Cancer Vaccine 59 diagnostic biomarkers 59 orally administered inhibitor 59 OTCBB CVBT 59 Abraxis Biosciences 59 Altair Therapeutics 59 Raven Biotechnologies 59 Dr. Wayne Danter 59 Solazed TM 59 Molecular Basis 59 JAK2 inhibitor 59 OvaRex R 59 Novel Oral 59 Antibody Drug Conjugate 59 Marinus Pharmaceuticals 59 Mouse Models 59 BIOCOM Investor Conference 59 Jean Jacques Garaud 59 Novel Mechanism 59 Files Investigational 59 Ambit Biosciences 59 Proteo 59 Antiviral Activity 59 Gastrointestinal Oncology 59 Juvaris BioTherapeutics 59 Cellerant Therapeutics 59 Vaughn M. Kailian 59 EnVivo Pharmaceuticals Inc. 59 product platforms AZX# 59 Gene Silencing 59 Preclinical 59 Autoimmune Diseases 59 Damian Marron 59 Onyx Pharmaceuticals Announces 59 Klaus Schollmeier Chief Executive 59 Tomas Leanderson 59 Phytomedics Inc. 59 Completes Enrollment 59 Milestone Payments 59 Callisto Pharmaceuticals 59 BioSante Pharmaceuticals NASDAQ BPAX 59 Molecular Pathogenesis 59 please visit http:/www.vandapharma.com 59 Guanilib 59 Cancer Stem Cells 59 Trodusquemine MSI 59 Avicena 59 AACR symposium 59 glucokinase activator 59 Alligator Bioscience AB 59 Phase 2a Trial 59 Spiro Rombotis President 59 tiapamil 59 2 methoxyestradiol 59 Cascade LifeSciences 59 Cytochrome P# 59 Stromedix 59 Plexxikon proprietary 59 Howard H. Pien 59 Glaxo Wellcome plc 59 Ceflatonin R 59 Small Molecules 59 BioGeneriX 59 Translational Medicine 59 Alseres Pharmaceuticals Inc. 59 www.ucb group.com 59 Oncolytic 59 Immusol 59 Karin Eastham 59 VisEn Medical 59 Factor VIIa 59 Nicotine Vaccine 59 Oligonucleotide 59 HQK 59 Nautilus Biotech 59 Ophthotech 59 OTC BB PVCT 59 Array BioPharma 59 Endocrinol 59 BioAxone 59 Pivotal Phase III 59 Preclinical Study 59 Intarcia 59 PDE4 inhibitor 59 Procyon Biopharma Inc. 59 FDA Accepts 59 Diasome 59 Mersana 59 ImmuneRegen BioSciences Inc. 59 Harold Van Wart 59 EnzymeRx 59 Tapestry Pharmaceuticals 59 NPC 1C 59 G Protein Coupled 59 therapeutic monoclonal antibody 59 acetonide FA 59 GlycoMimetics 59 Dr Bernd Hentsch 59 Semafore Pharmaceuticals 59 POTELLIGENT R Technology 59 therapeutic monoclonal antibodies 59 novel MetAP 2 59 J. Mazzo Ph.D. 59 Philippe Archinard Chief Executive 59 asthma COPD Chronic 59 Antibody Engineering 59 Diagnostic Immunology 59 Initiates Phase 2b 59 Product Commercialization 59 Pandemic Influenza Vaccines 59 Neogenix Oncology 59 4SC AG 59 Cylene 59 Karo Bio 59 Phase 2b Study 59 Akesis Pharmaceuticals 59 Trastuzumab DM1 59 Preclinical Efficacy 59 Zemiva TM 59 Anders Ekblom 59 Presents Preclinical 59 Vascular Targeting Agents 59 Neurodegenerative Disease 59 VentiRx Pharmaceuticals 59 Nasdaq PGNX today 59 Kosan dependence 59 Panzem R NCD 59 Acceleron Pharma 59 Prolongs Survival 59 Pervasis 59 Biotherapeutics 59 Ocrelizumab 59 Commercialize Novel 59 Cempra 59 Valera Pharmaceuticals 59 essential thrombocythemia ET 59 Aurora Kinase 59 Pluristem Therapeutics 59 J.P. Morgan Healthcare 59 Postdoctoral Position 59 Pharmacogenomic 59 AVI BioPharma Announces 59 FoldRx 59 Wolfgang Renner 59 Regenerative Cells 59 Novel Therapeutics 59 Alnylam Pharmaceuticals 59 YONDELIS R 59 Diatos 59 Alnylam Pharma 59 Pegloticase 59 Initiates Dosing 59 peptidic compound 59 midstage clinical 59 Tyrosine Kinase Inhibitor 59 Protein Biomarker 59 PhytoMedical Technologies Inc. 59 GSK Rare Diseases 59 Syntonix Pharmaceuticals 59 Lycera 59 Kleanthis G. Xanthopoulos Ph.D. 59 defensin mimetic antibiotic 59 cathepsin K inhibitor 59 QuatRx 59 acetylgalactosamine 6 59 Syndax 59 mertansine 59 epigenetic therapies 59 BioSante Pharmaceuticals Announces 59 HPV Vaccines 59 CancerVax Corporation 59 Erica Elchin #-#-# 59 RNA therapeutics 59 ENZON 59 Therion Biologics Corporation 59 Tolerx 59 Dr. Cauwenbergh 59 Zosano Pharma 59 Cheminformatics 59 First Patient Enrolled 59 Novel Inhibitor 59 Nasdaq CGEN 59 Idenix Pharmaceuticals 59 APT Pharmaceuticals 59 Flamel Technologies 59 Synergy Pharmaceuticals 59 beta 1a 59 TOPIGEN 59 http:/www.unigene.com 59 POSIDUR TM ELADUR TM 59 oral prodrug 59 TOPICA 59 Granted Orphan Drug 59 Alton Boynton 59 Anti infective 59 Aegerion 59 OMRIX Biopharmaceuticals 59 Epigenetics 59 Disease IBD 59 Anti CD# Antibody 59 Novartis Institutes 59 Progenics Pharmaceuticals 59 CYT# potent vascular disrupting 59 Cardioxyl Pharmaceuticals 59 Ryogen 59 Ostarine ™ 59 OTCBB PWRM.OB 59 OLGX 59 Phase Ib Clinical Trial 59 Nitazoxanide 59 Cenix BioScience 59 Pervasis Therapeutics Inc. 59 Supernus Pharmaceuticals 59 RhuDex 59 NOVAVAX 59 Metastatic Melanoma 59 Transdermal Delivery 59 FermaVir 59 Oral Fingolimod 59 NKT Therapeutics 59 Neurome 59 Recombinant Protein 59 motexafin gadolinium Injection 59 Michelle Dipp 59 Oxford Genome Sciences 59 DiaKine 59 Malaria Vaccine 59 ExonHit Therapeutics 59 Tumour Vascular Disrupting Agent 59 Mark Leuchtenberger 59 CRLX# 59 R roscovitine 59 Ortho Biotech Oncology 59 depsipeptide 59 NLV Partners 59 ANAVEX 59 Kuvan TM sapropterin 59 Oral Presentations 59 Initiates Clinical Trials 58 AVXL 58 www.pranabio.com 58 Prof. Desire Collen 58 Velcura Therapeutics 58 Phase III Pivotal 58 Dr. Gamzu 58 NASDAQ LIPD 58 Arriva Pharmaceuticals 58 Pepscan 58 Kevin Rakin 58 Veterinary Vaccines 58 Oral Calcitonin 58 Jeremy Curnock Cook 58 Antiangiogenic 58 NanoViricides 58 Blinatumomab 58 Therapeutic Proteins 58 Extracellular Matrix 58 Lupus Drug 58 cetuximab Erbitux R 58 Oligonucleotides 58 GTC NASDAQ GTCB 58 Celsion Corporation 58 Sirona Biochem 58 Kelly Luethje #-#-# 58 Therapeutic Antibodies 58 Pervasis Therapeutics 58 Taiho Pharmaceutical 58 Initiates Phase 58 Aganocide 58 Sapacitabine 58 Dendritic Cells 58 PharmD Ardea 58 Evotec AG 58 Genocea Biosciences 58 Dr. Aiping Young 58 MassGeneral Institute 58 June Almenoff MD 58 Febuxostat 58 MCSP respectively 58 ThermoDox ® clinical 58 http:/www.pharmacopeia.com 58 Cancer Therapies 58 Ozarelix 58 cisplatin carboplatin 58 mitogen activated ERK kinase 58 Neurobiological Technologies 58 Cytometry 58 BioLife Solutions 58 Aegerion Pharmaceuticals 58 Argenta Discovery 58 neuronal nicotinic receptors NNRs 58 Submits Biologics License Application 58 Halozyme Therapeutics 58 PEGylation 58 KYTHERA Biopharmaceuticals Inc. 58 Nonclinical 58 Melior Discovery 58 Ismail Kola 58 Nasdaq NRGN 58 Visit www.BASInc.com 58 Idun Pharmaceuticals 58 Shows Promise Against 58 Vysis 58 Enzon Pharmaceuticals 58 Silence Therapeutics plc 58 NASDAQ ADLR 58 Carl Spana Ph.D. 58 Astex Therapeutics 58 PharmaMar 58 mGluR2 positive 58 Shows Efficacy 58 Louis Drapeau 58 Phenomix 58 David Sidransky 58 Deborah Dunsire 58 ISTO 58 SPL# Gel vaginal microbicide 58 Tranzyme Pharma 58 Mohammad Azab MD 58 Inflazyme Pharmaceuticals 58 Cerenis Therapeutics 58 Evoltra ® 58 Marc de Garidel 58 Nasdaq IDIX biopharmaceutical 58 KineMed 58 Stapled Peptide 58 Cardiovascular Metabolic 58 Ocera Therapeutics 58 ospemifene 58 Fragment Based 58 OMP #R# 58 Oncogene Science 58 Affinium Pharmaceuticals 58 PEG SN# 58 OMRIX Biopharmaceuticals Inc. 58 Hedgehog Pathway Inhibitor 58 recombinant biopharmaceutical 58 PF # [002] 58 Immunotope 58 Chronogen 58 Zafgen 58 Emer Leahy 58 Idenix Novartis 58 George Migausky 58 Initiate Clinical Trial 58 Drug Shows Promise 58 NASDAQ AVEO 58 Kathleen Danenberg 58 Molecular Pharmacology 58 Apexigen 58 Functional Genomics 58 BTG plc 58 Targeted Therapies 58 Lexicon Genetics Incorporated 58 Dan Passeri 58 Ocular Diseases 58 WeissComm Partners +#-#-#-# 58 Naurex 58 Optimata 58 Malignancies 58 Prodarsan R 58 Gelesis 58 Mutagenesis 58 Maxine Gowen Ph.D. 58 Scientific Advisory Boards 58 Genospectra 58 muscarinic receptor agonist 58 Metabolic Profiling 58 miRagen Therapeutics 58 Christian Itin 58 Paolo Paoletti 58 Biomarin 58 Enzyme Replacement Therapy 58 Tumor Targeting 58 Iloperidone 58 Cell Therapies 58 Proprietary Products 58 Adolor Corporation 58 Investigational Drug 58 adenosine A2A 58 Oral Insulin 58 A3 adenosine receptor 58 Therapeutic Competitors 58 Novosom 58 Virosome Biologicals 58 Nasdaq PARD 58 Sirius Genomics 58 Pieris AG 58 BXT # 58 kidney urologic 58 OTCBB FCSC 58 Clavis Pharma 58 NASDAQ SNTA 58 INSPIRE Trial Phase III 58 sirtuin therapeutics 58 Biodesix 58 NDA Submission 58 GENFIT 58 Akebia Therapeutics 58 Novel Vaccine 58 Abbie Celniker Ph.D. 58 Vicriviroc 58 Annamycin 58 William H. Rastetter 58 Nanoemulsion 58 Nasdaq ACAD 58 BioCentury Future Leaders 58 Wolfgang Plischke 58 Tobira Therapeutics 58 KRYSTEXXA TM pegloticase 58 LibiGel ® 58 include GALNS N 58 Calistoga Pharmaceuticals 58 GSK # 58 HuCAL PLATINUM R 58 Tacere 58 Emerging Therapies 58 Patient Recruitment 58 ActivX 58 Nitec Pharma 58 Prabhavathi Fernandes Ph.D. 58 Judy C. Lewent 58 Lymphoid 58 Transcept Pharmaceuticals 58 Renal Cell Cancer 58 Isis Pharma 58 Antitumor Activity 58 ImmunoCellular 58 InteKrin 58 Power3 Medical 58 TheraGenetics 58 Nancy Wysenski 58 Oxxon Therapeutics 58 Cancer Therapeutic 58 Dr. Philip Toleikis 58 Saegis Pharmaceuticals 58 Epeius Biotechnologies Corporation 58 HealthCare Ventures 58 Dr. Scangos 58 Ventaira Pharmaceuticals 58 Cambridge Healthtech Institute 58 Alnylam Biotherapeutics 58 myelofibrosis polycythemia vera 58 Roland Haefeli 58 Velcura 58 Singulex 58 sodium thiosulfate STS 58 Receives Complete Response 58 EpiTherapeutics 58 Neural Stem Cell 58 Psyadon Pharmaceuticals 58 TRX1 58 Inhalation Solution 58 Philippe Calais 58 Scaffold Based 58 including eniluracil ADH 58 Pharmaceuticals Initiates 58 Jay Lichter 58 www.ucb.com 58 Intarcia Therapeutics Inc. 58 Monoclonal 58 RNA antagonists 58 Potent Antiviral Activity 58 Unither Pharmaceuticals 58 Clinical Efficacy 58 stated Avtar Dhillon 58 Dr. Drakeman 58 Errol De Souza 58 Fidelity Biosciences 58 Presidio Pharmaceuticals 58 Deepak Srivastava MD 58 Uli Hacksell Ph.D. 58 Potelligent Technology 58 seliciclib CYC# 58 PHX# 58 Neck Cancers 58 Kiadis Pharma 58 Stem Cell Transplant 58 Demetrius Pohl 58 Fresenius Biotech 58 Boehringer Mannheim 58 JAK Inhibitor 58 Milestone Payment From 58 Protein Polymer Technologies 58 Lantibio 58 Neuro Oncology Program 58 Chemotherapeutic Agents 58 antisense inhibitors 58 Osteoporosis Drug 58 HDL Selective Delipidation 58 VARI Laboratory 58 Nasdaq ONXX 58 proteasome inhibitor 58 Angiocept 58 Steve Worland Ph.D. 58 Alnylam #x# 58 AIM SLN 58 Dr. Damaj 58 Previously Treated 58 DiscoveryBioMed 58 candidates Azedra 58 Circ Pharma 57 immunologic diseases 57 Neuraltus 57 ASCO GI 57 SAR# [002] 57 Nanobiotix 57 ENMD # 57 Drug Fails 57 Bassil Dahiyat Ph.D. 57 Cutaneous Oncology 57 Combination REOLYSIN R 57 Cell Transplant 57 Genfit 57 Immune Disease 57 Mitchel Sayare 57 Viralytics 57 AmpliMed 57 HIV integrase inhibitor 57 Xencor 57 vitro pharmacology 57 Namenda Memantine HCl 57 Tokai Pharmaceuticals 57 PregLem 57 Cytochroma 57 SoluBest 57 TSX VIR 57 Study Evaluating 57 Jennerex 57 PNP inhibitor 57 FASN 57 torezolid phosphate 57 Preclinical Models 57 Bucindolol